Capital World Investors Raises Stock Holdings in Eli Lilly and Company $LLY

Capital World Investors increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.4% during the fourth quarter, HoldingsChannel reports. The fund owned 15,031,750 shares of the company’s stock after buying an additional 61,851 shares during the quarter. Eli Lilly and Company comprises about 2.2% of Capital World Investors’ portfolio, making the stock its 9th largest holding. Capital World Investors’ holdings in Eli Lilly and Company were worth $16,154,619,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Capital International Sarl grew its position in Eli Lilly and Company by 14.6% during the 4th quarter. Capital International Sarl now owns 147,081 shares of the company’s stock worth $158,065,000 after acquiring an additional 18,699 shares during the last quarter. Capital International Ltd. CA grew its position in Eli Lilly and Company by 6.5% during the 4th quarter. Capital International Ltd. CA now owns 73,237 shares of the company’s stock worth $78,706,000 after acquiring an additional 4,497 shares during the last quarter. Capital Group Investment Management PTE. LTD. grew its position in Eli Lilly and Company by 7.2% during the 4th quarter. Capital Group Investment Management PTE. LTD. now owns 16,150 shares of the company’s stock worth $17,356,000 after acquiring an additional 1,089 shares during the last quarter. Los Angeles Capital Management LLC grew its position in Eli Lilly and Company by 13.0% during the 4th quarter. Los Angeles Capital Management LLC now owns 260,276 shares of the company’s stock worth $279,713,000 after acquiring an additional 29,980 shares during the last quarter. Finally, Tradition Wealth Management LLC grew its position in Eli Lilly and Company by 3.8% during the 4th quarter. Tradition Wealth Management LLC now owns 1,916 shares of the company’s stock worth $2,059,000 after acquiring an additional 70 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Truist Financial restated a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, May 21st. HSBC downgraded Eli Lilly and Company from a “hold” rating to a “reduce” rating and cut their target price for the stock from $1,070.00 to $850.00 in a report on Tuesday, March 17th. Cantor Fitzgerald lifted their target price on Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an “overweight” rating in a report on Friday, May 1st. Finally, Bank of America lifted their target price on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $1,227.00.

Eli Lilly and Company Stock Up 0.7%

Shares of LLY opened at $1,133.15 on Friday. The company has a market capitalization of $1.07 trillion, a PE ratio of 40.25, a PEG ratio of 1.24 and a beta of 0.53. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The stock’s 50-day moving average price is $974.59 and its two-hundred day moving average price is $1,013.04. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,166.29.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm’s revenue was up 55.5% compared to the same quarter last year. During the same period in the previous year, the business earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, analysts anticipate that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company’s payout ratio is currently 24.58%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark reversed its earlier exclusion and will now cover Eli Lilly’s Zepbound, a meaningful reimbursement win that could expand patient access and bolster obesity-drug sales. Article Title
• Positive Sentiment: WeightWatchers Med+ is now available through LillyDirect, reinforcing Lilly’s distribution ecosystem and strengthening its leadership in chronic weight management. Article Title
• Positive Sentiment: Lilly announced a new Phase 2b obesity trial for macupatide–eloralintide, adding another potential growth driver to its weight-loss pipeline beyond current GLP-1 products. Article Title
• Positive Sentiment: Jim Cramer highlighted Lilly as a potential winner against competitors, with attention on its new pill version of its weight-loss drug and broader competitive advantages. Article Title
• Positive Sentiment: Analysts and market commentary continue to frame LLY as a long-term winner, citing strong execution, deal-making, and diversification efforts beyond obesity drugs. Article Title
• Neutral Sentiment: Lilly also received coverage around its Phase 3 Libretto-432 cancer study and a $1.9 billion Ascidian partnership, both of which support the pipeline but are longer-term in nature. Article Title
• Neutral Sentiment: Broader health-care sector commentary and stock-screen articles were generally supportive, but they are less likely to be a direct driver of LLY’s move than the CVS and pipeline news. Article Title

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.